Bioshares is Australia's leading biotech stock report. Bioshares delivers independent investment research to investors on Australian biotech, pharmaceutical and healthcare companies.
Bioshares is published by Blake Industry and Market Analysis Pty Ltd. It was first published as a quarterly hardcopy report in 2000. From edition 13 onwards, Bioshares has been published on a weekly basis and moved to a fortnight edition in 2021. It is distributed in an electronic format.
Bioshares has covered the biotech sector from its days of obscurity in 1999, through the boom in 2000, through the downturn in 2001 and 2002 and has been the first choice for investment research by numerous biotech investors in the 2003 biotech upswing.
About Blake Industry and Market Analysis Pty Ltd
Blake Industry and Market Analysis Pty Ltd (BIMA) was founded in 1998 by Mark Pachacz and David Blake, with the goal of delivering independent investment research about pharmaceutical and biotechnology companies to stockbrokers, fund managers and other clients. BIMA is a licensed investment advisory firm with the Australian Investment and Securities Commission.
In 2005 the first Bioshares Biotech Summit was held, as a high-level investment forum for Australia’s biotech investment sector. In 2011 the event was moved to Queenstown, New Zealand, and was moved to Albury in 2022 during the coronavirus pandemic.
Mark Pachacz is a chemical engineer by training. He is a graduate of Monash University and the Securities Institute of Australia.
In 2021, sadly David Blake passed away after a battle with lung cancer. He was 59. In honour of David, the annual Blake Award for Excellence has been formed with the inaugural winner in 2022 being Telix Pharmaceuticals.